LV10432B - Neuromuscular transmission blocators - Google Patents
Neuromuscular transmission blocators Download PDFInfo
- Publication number
- LV10432B LV10432B LVP-92-334A LV920334A LV10432B LV 10432 B LV10432 B LV 10432B LV 920334 A LV920334 A LV 920334A LV 10432 B LV10432 B LV 10432B
- Authority
- LV
- Latvia
- Prior art keywords
- cis
- atracurium
- umc
- salt
- physiologically acceptable
- Prior art date
Links
- 230000005540 biological transmission Effects 0.000 title claims 2
- 230000002232 neuromuscular Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960000358 cisatracurium Drugs 0.000 claims 4
- 230000003287 optical effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical class C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010029315 Neuromuscular blockade Diseases 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 101100191164 Mus musculus Ppcs gene Proteins 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- IRIIKYVSZMJVNX-UHFFFAOYSA-N 2,4,6-tris(2-methylaziridin-1-yl)-1,3,5-triazine Chemical compound CC1CN1C1=NC(N2C(C2)C)=NC(N2C(C2)C)=N1 IRIIKYVSZMJVNX-UHFFFAOYSA-N 0.000 description 1
- 241001351283 Arta Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000755093 Gaidropsarus vulgaris Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000557752 Khaya Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 101150115538 nero gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Semiconductor Lasers (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Led Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Paper (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909015473A GB9015473D0 (en) | 1990-07-13 | 1990-07-13 | Neuromuscular blocking agents |
| PCT/GB1991/001150 WO1992000965A1 (en) | 1990-07-13 | 1991-07-12 | Neuromuscular blocking agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10432A LV10432A (lv) | 1995-02-20 |
| LV10432B true LV10432B (en) | 1995-08-20 |
Family
ID=10679071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-92-334A LV10432B (en) | 1990-07-13 | 1992-12-18 | Neuromuscular transmission blocators |
Country Status (40)
| Country | Link |
|---|---|
| EP (1) | EP0539470B1 (it) |
| JP (3) | JP2823356B2 (it) |
| KR (1) | KR0174284B1 (it) |
| AT (1) | ATE138369T1 (it) |
| AU (2) | AU8190491A (it) |
| BE (1) | BE1003407A3 (it) |
| CA (1) | CA2087104C (it) |
| CH (1) | CH683427A5 (it) |
| CY (1) | CY1985A (it) |
| CZ (1) | CZ284645B6 (it) |
| DE (2) | DE4191541T1 (it) |
| DK (2) | DK0539470T3 (it) |
| ES (2) | ES2088009T3 (it) |
| FI (2) | FI103507B1 (it) |
| FR (1) | FR2665701B1 (it) |
| GB (2) | GB9015473D0 (it) |
| GE (1) | GEP19981163B (it) |
| GR (1) | GR3020792T3 (it) |
| HK (1) | HK80196A (it) |
| HU (2) | HU218766B (it) |
| IE (1) | IE912440A1 (it) |
| IL (1) | IL98814A (it) |
| IT (1) | IT1249677B (it) |
| LT (1) | LT3317B (it) |
| LU (1) | LU88198A1 (it) |
| LV (1) | LV10432B (it) |
| MX (1) | MX9203220A (it) |
| MY (1) | MY113017A (it) |
| NL (1) | NL9120017A (it) |
| NZ (1) | NZ238964A (it) |
| PA (1) | PA8401801A1 (it) |
| PL (1) | PL167302B1 (it) |
| PT (1) | PT98306B (it) |
| RU (1) | RU2104005C1 (it) |
| SA (1) | SA91120073B1 (it) |
| SE (1) | SE9300052L (it) |
| SK (1) | SK383392A3 (it) |
| UA (1) | UA32536C2 (it) |
| WO (1) | WO1992000965A1 (it) |
| ZA (1) | ZA915468B (it) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453510A (en) * | 1990-07-13 | 1995-09-26 | Burroughs Wellcome Co. | Neuromuscular blocking agents |
| DE19535762A1 (de) * | 1995-09-26 | 1997-03-27 | Basf Ag | Verfahren zur Racematspaltung |
| US5684154A (en) * | 1996-02-16 | 1997-11-04 | Abbott Laboratories | Process for the preparation and isolation of atracurium besylate |
| CA2284802C (en) * | 1997-03-25 | 2009-06-16 | Cornell Research Foundation, Inc. | Substituted isoquinolines as ultra short acting neuromuscular blockers |
| AU2008222298A1 (en) | 2007-03-08 | 2008-09-12 | Chemagis Ltd. | (1R,1'R)-atracurium salts separation process |
| AU2008231470A1 (en) * | 2007-03-26 | 2008-10-02 | Chemagis Ltd. | (1R,1'R)-atracurium salts separation process |
| WO2008132748A1 (en) | 2007-05-01 | 2008-11-06 | Chemagis Ltd. | Process for producing cisatracurium compounds and associated intermediates |
| WO2008132746A1 (en) | 2007-05-01 | 2008-11-06 | Chemagis Ltd. | Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates |
| CA2687157A1 (en) * | 2007-06-18 | 2008-12-24 | Chemagis Ltd. | (1r,1'r)-atracurium salts separation process |
| CN101337935B (zh) * | 2007-07-06 | 2011-01-12 | 江苏恒瑞医药股份有限公司 | 一种用两相萃取法纯化苯磺酸阿曲库铵的方法 |
| CN101337936B (zh) * | 2007-07-06 | 2011-03-23 | 江苏恒瑞医药股份有限公司 | 一种用柱色谱法纯化苯磺酸阿曲库铵的方法 |
| BRPI0816519A2 (pt) | 2007-10-29 | 2015-03-24 | Chemagis Ltd | Processo para preparar um sal de r, r'-atracúrio isomericamente enriquecido e sal de r, r'-atracúrio |
| IT1396543B1 (it) | 2008-07-16 | 2012-12-14 | Farmabios Spa | Processo per la purificazione di bloccanti neuromuscolari |
| WO2010128518A2 (en) * | 2009-05-04 | 2010-11-11 | Gland Pharma Limited | Novel process for the preparation of cisatracurium besylate |
| CN107056700A (zh) * | 2017-04-18 | 2017-08-18 | 哈尔滨医科大学 | 一种四氢异喹啉类化合物外消旋体的半量拆分法 |
| CN112939862B (zh) * | 2021-02-03 | 2023-01-10 | 江苏诚信药业有限公司 | 一种苯磺顺阿曲库铵杂质h的分离制备方法及其应用 |
| CN115850169A (zh) * | 2022-10-17 | 2023-03-28 | 上海医药集团(本溪)北方药业有限公司 | 苯磺顺阿曲库铵杂质及其中间体的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3004031A (en) * | 1958-07-03 | 1961-10-10 | Allen & Hauburys Ltd | Diquaternary salts of papaverino esters |
| AU506657B2 (en) | 1975-12-10 | 1980-01-17 | Wellcome Foundation Limited, The | Isoquinoline derivatives |
| GB1579822A (en) * | 1976-10-29 | 1980-11-26 | Wellcome Found | Tetrahydroisoquinolinium muscle relaxants |
| ES454090A1 (es) * | 1976-12-09 | 1978-01-16 | Wellcome Found | Un metodo para preparar compuestos heterociclicos. |
| DE3328664A1 (de) * | 1983-08-09 | 1985-02-21 | Robert Bosch Gmbh, 7000 Stuttgart | Zuckerziehmaschine |
| BG41897A1 (en) * | 1985-07-19 | 1987-09-15 | Ivanov | Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation |
-
1990
- 1990-07-13 GB GB909015473A patent/GB9015473D0/en active Pending
-
1991
- 1991-07-12 NZ NZ238964A patent/NZ238964A/en not_active IP Right Cessation
- 1991-07-12 IL IL9881491A patent/IL98814A/en not_active IP Right Cessation
- 1991-07-12 DK DK91913479.1T patent/DK0539470T3/da active
- 1991-07-12 EP EP91913479A patent/EP0539470B1/en not_active Expired - Lifetime
- 1991-07-12 ES ES91913479T patent/ES2088009T3/es not_active Expired - Lifetime
- 1991-07-12 FR FR9108805A patent/FR2665701B1/fr not_active Expired - Lifetime
- 1991-07-12 KR KR1019930700072A patent/KR0174284B1/ko not_active IP Right Cessation
- 1991-07-12 IE IE244091A patent/IE912440A1/en not_active IP Right Cessation
- 1991-07-12 HU HU9300052A patent/HU218766B/hu unknown
- 1991-07-12 PL PL91297606A patent/PL167302B1/pl unknown
- 1991-07-12 BE BE9100665A patent/BE1003407A3/fr not_active IP Right Cessation
- 1991-07-12 SK SK3833-92A patent/SK383392A3/sk not_active IP Right Cessation
- 1991-07-12 PT PT98306A patent/PT98306B/pt not_active IP Right Cessation
- 1991-07-12 CH CH857/92A patent/CH683427A5/fr not_active IP Right Cessation
- 1991-07-12 NL NL9120017A patent/NL9120017A/nl not_active Application Discontinuation
- 1991-07-12 ES ES09250007A patent/ES2083315B1/es not_active Expired - Lifetime
- 1991-07-12 CA CA002087104A patent/CA2087104C/en not_active Expired - Fee Related
- 1991-07-12 AT AT91913479T patent/ATE138369T1/de not_active IP Right Cessation
- 1991-07-12 MY MYPI91001260A patent/MY113017A/en unknown
- 1991-07-12 AU AU81904/91A patent/AU8190491A/en not_active Abandoned
- 1991-07-12 UA UA93101147A patent/UA32536C2/uk unknown
- 1991-07-12 RU RU93004869A patent/RU2104005C1/ru active
- 1991-07-12 CZ CS923833A patent/CZ284645B6/cs not_active IP Right Cessation
- 1991-07-12 WO PCT/GB1991/001150 patent/WO1992000965A1/en active IP Right Grant
- 1991-07-12 IT ITRM910518A patent/IT1249677B/it active IP Right Grant
- 1991-07-12 ZA ZA915468A patent/ZA915468B/xx unknown
- 1991-07-12 JP JP3512229A patent/JP2823356B2/ja not_active Expired - Lifetime
- 1991-07-12 DE DE19914191541 patent/DE4191541T1/de not_active Withdrawn
- 1991-07-12 DE DE69119768T patent/DE69119768T2/de not_active Expired - Lifetime
- 1991-08-18 SA SA91120073A patent/SA91120073B1/ar unknown
-
1992
- 1992-06-24 MX MX9203220A patent/MX9203220A/es unknown
- 1992-11-26 GB GB9224764A patent/GB2260763B/en not_active Expired - Lifetime
- 1992-12-09 LU LU88198A patent/LU88198A1/fr unknown
- 1992-12-14 DK DK921496A patent/DK149692D0/da not_active Application Discontinuation
- 1992-12-18 LV LVP-92-334A patent/LV10432B/lv unknown
- 1992-12-28 FI FI925894A patent/FI103507B1/fi not_active IP Right Cessation
- 1992-12-30 LT LTIP274A patent/LT3317B/lt not_active IP Right Cessation
-
1993
- 1993-01-12 SE SE9300052A patent/SE9300052L/xx not_active Application Discontinuation
- 1993-07-26 GE GEAP19931161A patent/GEP19981163B/en unknown
-
1995
- 1995-01-23 AU AU11346/95A patent/AU687481B2/en not_active Expired
- 1995-05-12 HU HU95P/P00131P patent/HU211169A9/hu unknown
-
1996
- 1996-05-09 HK HK80196A patent/HK80196A/xx not_active IP Right Cessation
- 1996-08-14 GR GR960402172T patent/GR3020792T3/el unknown
- 1996-11-14 PA PA19968401801A patent/PA8401801A1/es unknown
-
1997
- 1997-09-05 CY CY198597A patent/CY1985A/xx unknown
- 1997-09-08 JP JP9242598A patent/JPH10139763A/ja active Pending
-
1998
- 1998-10-28 FI FI982342A patent/FI982342A0/fi unknown
-
2000
- 2000-09-05 JP JP2000268819A patent/JP3462165B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV10432B (en) | Neuromuscular transmission blocators | |
| Sidoroff et al. | Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern | |
| ES2197201T3 (es) | Tratamiento de la neuritis optica. | |
| Thyagarajan et al. | Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study | |
| Bicart-Sée et al. | Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS | |
| Fu et al. | Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses | |
| Uchida et al. | Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism | |
| Neumann et al. | Sodium butyrate: a chemical inducer of in vivo reactivation of herpes simplex virus type 1 in the ocular mouse model | |
| TSUTSUMI et al. | The treatment of neuroleptic malignant syndrome using dantrolene sodium | |
| Cozzani et al. | Ciprofloxacin as a trigger for bullous pemphigoid: the second case in the literature | |
| Cholongitas et al. | Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? | |
| Yaffe | Comparative efficacy of aspirin and acetaminophen in the reduction of fever in children | |
| Liu et al. | Ubiquitination of SARS-CoV-2 ORF7a prevents cell death induced by recruiting BclXL to activate ER stress | |
| Rigos et al. | Temperature‐dependent pharmacokinetics and tissue distribution of oxolinic acid in sea bass, Dicentrarchus labrax L., after a single intravascular injection | |
| Chen et al. | Acute Otitis due to Vibrio fluvialis after Swimming | |
| Levy et al. | Anaesthesia for patients with hereditary arrhythmias; part 2: congenital long QT syndrome and arrhythmogenic right ventricular cardiomyopathy | |
| Ferrándiz‐Pulido et al. | Secondary syphilis with liver involvement in a liver transplant recipient | |
| Hussain et al. | Maternal methadone may cause arrhythmias in neonates | |
| Chen et al. | Successful treatment of pulmonary hemorrhage associated with leptospirosis and scrub typhus coinfection by early plasma exchange | |
| Ishida et al. | Favorable outcome with direct‐acting antiviral treatment in hepatitis C patients coinfected with HIV | |
| CA2181901A1 (en) | Pyridazinone derivatives | |
| Seki et al. | Cardiac tamponade caused by spontaneous rupture of mediastinal lymph node metastasis of hepatocellular carcinoma | |
| Toyoda et al. | Eight‐week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response | |
| Sidell et al. | The reversal of anticholinergic intoxication in man with the cholinesterase inhibitor VX | |
| Basak et al. | Lack of response to isotretinoin in annular elastolytic giant cell granuloma |